活体供肾——PAK与SPK：如何抉择？
Live donor kidney - PAK versus SPK: how to decide?
作者信息
Stites Erik, Wiseman Alexander C
机构信息
Division of Renal Diseases and Hypertension, Transplant Center, University of Colorado Denver, Aurora, Colorado, USA.
出版信息
Curr Opin Organ Transplant. 2017 Aug;22(4):377-381. doi: 10.1097/MOT.0000000000000435.
PURPOSE OF REVIEW
Patients with type 1 diabetes and end stage renal disease face a complex choice when considering the relative risks and benefits of kidney transplant alone with or without subsequent pancreas after kidney transplant (PAK) or simultaneous kidney pancreas transplant (SPK).
RECENT FINDINGS
SPK is considered the optimal treatment regarding long-term patient survival, but when also faced with the option of living donor kidney transplant with the potential for PAK later, the ideal option is less clear.
SUMMARY
This review summarizes the current literature regarding SPK, living donor kidney transplant alone, and PAK transplant outcomes and examines the relative risks of pre- and posttransplant variables that impact patient and graft survival to help inform this complex treatment decision.
综述目的
1型糖尿病合并终末期肾病患者在考虑单纯肾移植、肾移植后是否进行胰腺移植（PAK）或同时进行肾胰腺移植（SPK）的相对风险和益处时面临复杂选择。
最新发现
就患者长期生存而言，SPK被认为是最佳治疗方法，但当面临活体供肾移植及之后可能进行PAK的选择时，理想方案就不那么明确了。
总结
本综述总结了关于SPK、单纯活体供肾移植以及PAK移植结果的当前文献，并研究了影响患者和移植物存活的移植前和移植后变量的相对风险，以帮助为这一复杂的治疗决策提供信息。
Zotero 插件